Shoulder Innovations, Inc. (SI) shareholders
Close on Nov 17, 2026Market cap $428.04MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| FMR LLC Joint filing with Abigail P. Johnson (19.00%) | 3,848,791 | 19.00% | 13G (passive) | Aug 29, 2025 |
| Abigail P. Johnson Joint filing with FMR LLC (17.70%) | 3,673,960 | 17.70% | 13G (passive) amendment | Jun 30, 2026 |
| Casey M. Tansey Joint filing with Presidio Management Group XII, L.L.C. (13.10%), U.S. Venture Partners XII, L.P. (8.20%) | 2,740,787 | 13.30% | 13G (passive) | Sep 30, 2025 |
| Martemanshurk B.V. Joint filing with Gilde Healthcare Holding B.V. (10.70%), Gilde Healthcare V Management B.V. (10.70%) and 2 more | 2,212,207 | 10.70% | 13D (active) amendment | Aug 5, 2026 |
| Henry A. Plain Jr. Joint filing with LSV Associates II, LLC (9.30%), Michael A Carusi (9.30%) and 2 more | 1,885,136 | 9.30% | 13G (passive) | Sep 30, 2025 |
| Churchill R. Sean Joint filing with cultivate(MD) Holdings, LLC (6.70%), Blue David Lawrence (6.70%) and 2 more | 1,363,394 | 6.70% | 13G (passive) | Sep 30, 2025 |
| Arboretum Investment Manager VI, LLC Joint filing with Arboretum Ventures VI, L.P. (5.80%), Jan L. Garfinkle (5.80%) and 2 more | 1,163,891 | 5.80% | 13G (passive) | Aug 1, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SI | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| FMR LLC | 3,673,960 | 17.65% | $74.51M | −110,592 | 0.00% |
| BlackRock, Inc. | 638,420 | 3.07% | $12.95M | +82,368 | 0.00% |
| Sectoral Asset Management Inc | 430,407 | 2.07% | $8.73M | – | 6.09% |
| Vanguard Capital Management LLC | 392,181 | 1.88% | $7.95M | −21,299 | 0.00% |
| KCM Capital Inc | 300,000 | 1.44% | $6.08M | +265,000 | 0.98% |
| TimesSquare Capital Management, LLC | 298,219 | 1.43% | $6.05M | −24,545 | 88.95% |
| Roubaix Capital, LLC | 255,288 | 1.23% | $5.18M | −1,833 | 1.86% |
| Driehaus Capital Management LLC | 253,760 | 1.22% | $5.15M | New | 0.03% |
| Parkman Healthcare Partners LLC | 226,212 | 1.09% | $4.59M | New | 0.47% |
| Geode Capital Management, LLC | 199,529 | 0.96% | $4.05M | +15,850 | 0.00% |
| CM Management, LLC | 145,000 | 0.70% | $2.94M | +45,000 | 1.96% |
| JPMorgan Chase & Co | 124,437 | 0.60% | $2.62M | −6,274 | 0.00% |
| Morgan Stanley | 117,265 | 0.56% | $2.38M | −40,313 | 0.00% |
| State Street Corp | 114,859 | 0.55% | $2.33M | +21,614 | 0.00% |
| HighTower Advisors, LLC | 102,640 | 0.49% | $2.08M | New | 0.00% |
| Jane Street Group, LLC | 86,307 | 0.41% | $1.75M | New | 0.00% |
| Walleye Capital LLC | 86,155 | 0.41% | $1.75M | +972 | 0.01% |
| Schonfeld Strategic Advisors LLC | 77,737 | 0.37% | $1.58M | New | 0.01% |
| Northern Trust Corp | 71,291 | 0.34% | $1.45M | +7,224 | 0.00% |
| Vanguard Portfolio Management LLC | 70,335 | 0.34% | $1.43M | +9,338 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 72 | 8M | 39.8% | 24 / 30 | 11 / 9 | 2M | 1M |
| Q1 2026 | 58 | 8M | 36.6% | 16 / 24 | 9 / 7 | 2M | 0M |
| Q4 2025 | 50 | 7M | 31.8% | 13 / 12 | 16 / 5 | 1M | 1M |
| Q3 2025 | 42 | 7M | 35.2% | 42 / 0 | 0 / 0 | 7M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
91 funds held SI in Q2 2026, 17% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SI | Value | % of fund | As of |
|---|---|---|---|---|---|
| Select Medical Technology and Devices Portfolio | 947,763 | 4.55% | $13.93M | 0.47% | May 31, 2026 |
| Fidelity Small Cap Growth Fund | 777,617 | 3.74% | $17.68M | 0.20% | Jul 31, 2026 |
| Select Health Care Portfolio | 545,286 | 2.62% | $8.02M | 0.14% | May 31, 2026 |
| Fidelity Balanced Fund | 505,572 | 2.43% | $7.43M | 0.01% | May 31, 2026 |
| Fidelity Small Cap Growth K6 Fund | 387,903 | 1.86% | $8.82M | 0.19% | Jul 31, 2026 |
| Vanguard Total Stock Market Index Fund | 322,231 | 1.55% | $6.53M | 0.00% | Jun 30, 2026 |
| Fidelity Advisor Health Care Fund | 310,692 | 1.49% | $7.07M | 0.23% | Jul 31, 2026 |
| iShares Russell 2000 ETF | 264,648 | 1.27% | $5.37M | 0.01% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 114,700 | 0.55% | $2.61M | 0.01% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 87,838 | 0.42% | $1.78M | 0.01% | Jun 30, 2026 |
| JPMorgan Small Cap Value Fund | 76,733 | 0.37% | $1.56M | 0.12% | Jun 30, 2026 |
| VIP Balanced Portfolio | 68,600 | 0.33% | $1.39M | 0.02% | Jun 30, 2026 |
| AST Small-Cap Equity Portfolio | 66,815 | 0.32% | $1.36M | 0.06% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 56,418 | 0.27% | $1.14M | 0.00% | Jun 30, 2026 |
| Vanguard Russell 2000 Index Fund | 53,226 | 0.26% | $782.42K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Robert Joseph Ball | CEO & Executive Chairman, Director | 417,942 | 2.01% | Nov 2, 2026 |
| Matthew Fraser Ahearn | Chief Operating Officer, Director | 245,776 | 1.18% | Aug 18, 2026 |
| Jonathan E. Osborne | Chief Commercial Officer | 60,355 | 0.29% | Aug 10, 2026 |
| Jeffrey S. Points | Chief Financial Officer | 68,835 | 0.33% | Mar 17, 2026 |
| David Lawrence Blue | See Remarks | 139,372 | 0.67% | Feb 3, 2026 |
| Kevin K. Sidow | Director | 25,948 | 0.12% | Oct 6, 2026 |
| Casey M. Tansey | Director, 10% owner | 2,746,564 | 13.19% | Oct 6, 2026 |
| Paul Buckman | Director | 65,025 | 0.31% | Oct 6, 2026 |
| Andrew Hykes | Director | 7,438 | 0.04% | Oct 6, 2026 |
| Richard Buchholz | Director | 18,712 | 0.09% | Jun 29, 2026 |
| Michael A. Carusi | Director | 1,626,136 | 7.81% | Aug 5, 2025 |
| Geoffrey B. Pardo | Director, 10% owner | 2,288,148 | 10.99% | Aug 5, 2025 |
| Healthcare Holding B.V. Gilde | 10% owner | 2,185,914 | 10.50% | Aug 28, 2026 |
| Jean George | – | – | – | Aug 5, 2025 |
| LSV Associates II, LLC | – | – | – | Aug 5, 2025 |
| Lightstone Ventures II, L.P. | – | – | – | Aug 5, 2025 |
| Henry A. Plain JR | – | – | – | Aug 5, 2025 |
| Lightstone Ventures II (A), L.P. | – | 1,885,136 | 9.05% | Aug 5, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Robert Joseph Ball CEO & Executive Chairman, Director | Oct 30, 2026 | Tax withholding | −29,639 | $20.44 | $605.82K | 417,942 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Oct 30, 2026 | Option exercise | +66,757 | $2.48 | $165.58K | 447,581 |
| Kevin K. Sidow Director | Oct 5, 2026 | Award | +892 | $19.60 | $17.48K | 25,948 |
| Andrew Hykes Director | Oct 5, 2026 | Award | +669 | $19.60 | $13.11K | 7,438 |
| Casey M. Tansey Director, 10% owner | Oct 5, 2026 | Award | +733 | $19.60 | $14.37K | 53,445 |
| Paul Buckman Director | Oct 5, 2026 | Award | +1,275 | $19.60 | $24.99K | 65,025 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Sep 14, 2026 | Option exercise | +89,233 | $2.10 | $187.39K | 390,999 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Sep 14, 2026 | Sale | −10,175 | $18.45 | $187.73K | 380,824 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 26, 2026 | Sale | −1,196 | $22.60 | $27.03K | 2,185,914 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 24, 2026 | Sale | −681 | $22.62 | $15.40K | 2,187,110 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 21, 2026 | Sale | −20,516 | $22.61 | $463.87K | 2,187,791 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 20, 2026 | Sale | −3,900 | $22.60 | $88.14K | 2,208,307 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −12,586 | $20.94 | $263.55K | 245,776 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 18, 2026 | Sale(10b5-1 plan) | −1,600 | $21.38 | $34.21K | 244,176 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 17, 2026 | Sale(10b5-1 plan) | −8,314 | $20.10 | $167.11K | 258,362 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Aug 14, 2026 | Gift | −2,500 | – | – | 266,676 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 6, 2026 | Sale | −2,095 | $22.60 | $47.35K | 2,212,207 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 5, 2026 | Sale | −7,338 | $22.64 | $166.13K | 2,214,302 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 4, 2026 | Sale | −99,812 | $22.77 | $2.27M | 2,221,640 |
| Healthcare Holding B.V. Gilde 10% owner | Aug 3, 2026 | Sale | −10,751 | $22.71 | $244.16K | 2,321,452 |
| Healthcare Holding B.V. Gilde 10% owner | Jul 31, 2026 | Sale | −20,034 | $22.73 | $455.37K | 2,332,203 |
| Healthcare Holding B.V. Gilde 10% owner | Jul 30, 2026 | Sale | −28,245 | $23.36 | $659.80K | 2,352,237 |
| Richard Buchholz Director | Jun 26, 2026 | Award | +5,046 | – | – | 18,712 |
| Kevin K. Sidow Director | Jun 26, 2026 | Award | +5,046 | – | – | 25,056 |
| Andrew Hykes Director | Jun 26, 2026 | Award | +5,046 | – | – | 6,769 |
| Casey M. Tansey Director, 10% owner | Jun 26, 2026 | Award | +5,046 | – | – | 52,712 |
| Paul Buckman Director | Jun 26, 2026 | Award | +5,046 | – | – | 63,750 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −2,500 | $19.26 | $48.15K | 269,176 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Jun 15, 2026 | Sale(10b5-1 plan) | −1,644 | $18.20 | $29.92K | 271,676 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Jun 12, 2026 | Sale(10b5-1 plan) | −15,856 | $18.68 | $296.19K | 273,320 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Apr 30, 2026 | Option exercise | +10,000 | $2.48 | $24.80K | 300,018 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Apr 20, 2026 | Option exercise | +14,243 | $2.86 | $40.73K | 286,765 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Apr 20, 2026 | Option exercise | +7,421 | $2.48 | $18.40K | 272,522 |
| Paul Buckman Director | Mar 13, 2026 | Option exercise | +26,205 | $2.10 | $55.03K | 65,710 |
| Paul Buckman Director | Mar 13, 2026 | Option exercise | +19,401 | $2.48 | $48.11K | 39,505 |
| Paul Buckman Director | Mar 13, 2026 | Tax withholding | −3,292 | $14.62 | $48.13K | 62,418 |
| Paul Buckman Director | Mar 13, 2026 | Tax withholding | −3,714 | $14.82 | $55.04K | 58,704 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Mar 13, 2026 | Buy | +2,200 | $15.18 | $33.40K | 278,866 |
| Jeffrey S. Points Chief Financial Officer | Mar 13, 2026 | Option exercise | +13,264 | $2.48 | $32.89K | 68,785 |
| Jeffrey S. Points Chief Financial Officer | Mar 13, 2026 | Buy | +2,000 | $15.00 | $30.00K | 70,785 |
| Richard Buchholz Director | Mar 13, 2026 | Buy | +1,000 | $14.84 | $14.84K | 13,666 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Feb 6, 2026 | Option exercise | +10,000 | $2.48 | $24.80K | 274,604 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Feb 6, 2026 | Option exercise | +2,062 | $2.10 | $4.33K | 276,666 |
| Matthew Fraser Ahearn Chief Operating Officer, Director | Dec 31, 2025 | Award | +477 | $12.16 | $5.80K | 215,856 |
| David Lawrence Blue See Remarks | Dec 31, 2025 | Award | +1,041 | $12.16 | $12.66K | 139,372 |
| Jeffrey S. Points Chief Financial Officer | Dec 31, 2025 | Award | +1,076 | $12.16 | $13.08K | 55,521 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Dec 31, 2025 | Award | +1,661 | $12.16 | $20.20K | 120,118 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Dec 12, 2025 | Buy | +3,900 | $14.89 | $58.07K | 118,457 |
| Jeffrey S. Points Chief Financial Officer | Dec 12, 2025 | Buy | +1,005 | $14.98 | $15.05K | 54,445 |
| Robert Joseph Ball CEO & Executive Chairman, Director | Dec 11, 2025 | Buy | +3,300 | $14.83 | $48.94K | 114,557 |
| Jeffrey S. Points Chief Financial Officer | Dec 11, 2025 | Buy | +995 | $14.65 | $14.58K | 53,440 |
| Robert Joseph Ball CEO & EXECUTIVE CHAIRMAN, Director | Sep 12, 2025 | Buy | +6,000 | $15.49 | $92.94K | 111,259 |
| Jeffrey S. Points CHIEF FINANCIAL OFFICER | Sep 12, 2025 | Buy | +1,600 | $15.67 | $25.07K | 52,445 |
| David Lawrence Blue SEE REMARKS | Sep 12, 2025 | Option exercise | +78,616 | $2.10 | $165.09K | 122,553 |
| David Lawrence Blue SEE REMARKS | Sep 12, 2025 | Option exercise | +15,778 | $2.48 | $39.13K | 138,331 |
| Robert Joseph Ball CEO & EXECUTIVE CHAIRMAN, Director | Sep 11, 2025 | Buy | +2,000 | $14.90 | $29.80K | 105,259 |
| Jeffrey S. Points CHIEF FINANCIAL OFFICER | Sep 11, 2025 | Option exercise | +13,264 | $2.48 | $32.89K | 50,845 |
| Matthew Fraser Ahearn CHIEF OPERATING OFFICER, Director | Sep 11, 2025 | Option exercise | +12,286 | $0.93 | $11.43K | 120,320 |
| Matthew Fraser Ahearn CHIEF OPERATING OFFICER, Director | Sep 11, 2025 | Option exercise | +16,443 | $2.48 | $40.78K | 215,379 |
| Matthew Fraser Ahearn CHIEF OPERATING OFFICER, Director | Sep 11, 2025 | Option exercise | +78,616 | $2.10 | $165.09K | 198,936 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Shoulder Innovations's stock actually held short. Settlement fails (shares not delivered on time) peaked at 4,339 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Robert Joseph Ball Officer, Director | Sep 14, 2026 | 10,175 | $187.71K | Sep 14, 2026 | Private Acquisition from Issuer/Affiliate |
| Matthew Fraser Ahearn Director, Officer | Aug 17, 2026 | 22,500 | $466.43K | Aug 17, 2026 | Preferred Equity Financing |
| Gilde Healthcare Holding B.V.; Cooperatieve Gilde Healthcare V U.A. 10% Stockholder | Jul 29, 2026 | 200,000 | $4.85M | Jul 29, 2026 | Private placement of Series D convertible preferred stock; converted into common stock upon IPO closing 08/01/2025. Holding period tacks under Rule 144(d)(3)(ii). |
| Matthew Fraser Ahearn Director, Officer | Jun 12, 2026 | 20,000 | $375.20K | Jun 12, 2026 | Preferred Equity Financing |
Congress trades
2 trades in Shoulder Innovations reported by 1 member of the House
| Member | Type | Traded | Amount | Filed |
|---|---|---|---|---|
| Christopher L. Jacobs NY27 | Sold | Nov 8, 2022 | $1K–15K | Dec 12, 2022 |
| Christopher L. Jacobs NY27 | Bought | Jul 18, 2022 | $1K–15K | Sep 9, 2022 53 days late |
See a number that looks wrong?